{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:27:40Z","timestamp":1793813260000,"version":"4.6.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.annonc.2026.09.002","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:50:50Z","timestamp":1789141850000},"page":"1480-1488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and antitumor activity of the first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3208-3106","authenticated-orcid":false,"given":"J.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1516-0998","authenticated-orcid":false,"given":"Y.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8103-0505","authenticated-orcid":false,"given":"J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2026.09.002_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2026.09.002_bib2","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2026.09.002_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.56142","article-title":"Incidence rate trends of breast cancer overall and by molecular subtype by race and ethnicity and Age","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.annonc.2026.09.002_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000508675","article-title":"Endocrine-resistant breast cancer: mechanisms and treatment","volume":"15","author":"Hartkopf","year":"2020","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.annonc.2026.09.002_bib5","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: a review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annonc.2026.09.002_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102670","article-title":"Current and emerging treatment approaches for hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"123","author":"Jhaveri","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annonc.2026.09.002_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241311379","article-title":"Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status","volume":"17","author":"Qiu","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.annonc.2026.09.002_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-26-520506","article-title":"Advanced triple-negative breast cancer: emerging therapies and a changing treatment landscape","volume":"46","author":"Hennessy","year":"2026","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.annonc.2026.09.002_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.annonc.2026.09.002_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2026.09.002_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10549-012-2289-9","article-title":"Role of epidermal growth factor receptor in breast cancer","volume":"136","author":"Masuda","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2026.09.002_bib12","first-page":"5094","article-title":"Conflicting roles of EGFR expression by subtypes in breast cancer","volume":"11","author":"Oshi","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.annonc.2026.09.002_bib13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1186\/s12885-018-4917-1","article-title":"Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer","volume":"18","author":"Luhtala","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2026.09.002_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102786","article-title":"Long road towards effective HER3 targeting in breast cancer","volume":"129","author":"Papa","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annonc.2026.09.002_bib15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2026.09.002_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2026.09.002_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251324889","article-title":"Toxicities and management strategies of emerging antibody-drug conjugates in breast cancer","volume":"17","author":"Kang","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.annonc.2026.09.002_bib17","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I\/II trial","volume":"41","author":"Krop","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.09.002_bib18","article-title":"422RO A phase 2 study of patritumab deruxtecan (HER3-DXd) in patients (pts) with metastatic breast cancer (MBC)","volume":"11","author":"Hamilton","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2026.09.002_bib19","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/cancers15041130","article-title":"Resistance to antibody-drug conjugates targeting HER2 in breast cancer: molecular landscape and future challenges","volume":"15","author":"Guidi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"suppl 17","key":"10.1016\/j.annonc.2026.09.002_bib20","article-title":"Izalontamab brengitecan (iza-bren) versus physician\u2019s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): a randomized phase III study","volume":"44","author":"Wu","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:31:38Z","timestamp":1793809898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426066342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0923753426066342"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.002","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and antitumor activity of the first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}